NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Forecast, Price & News $0.29 0.00 (0.00%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$0.29▼$0.3250-Day Range$0.26▼$0.3752-Week Range$0.20▼$2.08Volume141,368 shsAverage Volume526,146 shsMarket Capitalization$8.31 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Adial Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside929.2% Upside$3.00 Price TargetShort InterestHealthy1.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.28) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 stars 3.3 Analyst's Opinion Consensus RatingAdial Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Adial Pharmaceuticals has a forecasted upside of 929.2% from its current price of $0.29.Amount of Analyst CoverageAdial Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.14% of the outstanding shares of Adial Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently decreased by 22.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADIL. Previous Next 2.7 News and Social Media Coverage News SentimentAdial Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Adial Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for ADIL on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.22% of the stock of Adial Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.42% of the stock of Adial Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($0.28) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adial Pharmaceuticals (NASDAQ:ADIL) StockAdial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson & William B. Stilley in November 2010 and is headquartered in Charlottesville, VA.Read More Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Stock News HeadlinesJune 1, 2023 | finance.yahoo.comAdial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9thMay 28, 2023 | americanbankingnews.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 22.0% in MayJune 6, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>May 24, 2023 | americanbankingnews.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Forecasted to Earn Q2 2023 Earnings of ($0.09) Per ShareMay 13, 2023 | americanbankingnews.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest UpdateMay 12, 2023 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 12, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 12, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateJune 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 10, 2023 | finance.yahoo.comAdial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and BusinessApril 8, 2023 | americanbankingnews.comAnalysts Offer Predictions for Adial Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:ADIL)April 7, 2023 | americanbankingnews.comAdial Pharmaceuticals, Inc. Expected to Post Q1 2023 Earnings of ($0.14) Per Share (NASDAQ:ADIL)April 4, 2023 | finance.yahoo.comIs Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?March 31, 2023 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business UpdateMarch 31, 2023 | americanbankingnews.comShort Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Expands By 42.2%March 30, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business UpdateMarch 30, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business UpdateMarch 21, 2023 | finance.yahoo.comAdial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use DisorderMarch 8, 2023 | finance.yahoo.comAdial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14thMarch 8, 2023 | finance.yahoo.comAdial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14thMarch 7, 2023 | msn.comADIL Soars after Positive Regulatory UpdateMarch 6, 2023 | markets.businessinsider.comAdial Pharma Surges 80% On Update Of AD04March 6, 2023 | finance.yahoo.comAdial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use DisorderMarch 2, 2023 | finance.yahoo.comAdial Pharmaceuticals Schedules Business Update Conference CallMarch 1, 2023 | stockhouse.comAdial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct OfferingFebruary 28, 2023 | finance.yahoo.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL): Is Breakeven Near?February 27, 2023 | finance.yahoo.comAdial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct OfferingSee More Headlines ADIL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADIL Company Calendar Last Earnings3/30/2023Today6/06/2023Next Earnings (Estimated)8/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+933.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-281.54% Return on Assets-179.93% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book2.23Miscellaneous Outstanding Shares28,520,000Free Float22,466,000Market Cap$8.28 million OptionableNot Optionable Beta0.96 Key ExecutivesCary J. ClaibornePresident, Chief Executive Officer & DirectorJoseph TruluckChief Financial Officer, Secretary & TreasurerBankole A. JohnsonChief Medical OfficerJulien DimastromatteoVice President-ResearchAlex LugovoyChief Business OfficerKey CompetitorsGalmed PharmaceuticalsNASDAQ:GLMDGuardion Health SciencesNASDAQ:GHSIEnveric BiosciencesNASDAQ:ENVBBellicum PharmaceuticalsNASDAQ:BLCMNexImmuneNASDAQ:NEXIView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 131,287 shares on 5/16/2023Ownership: 0.779%Renaissance Technologies LLCSold 150,986 shares on 5/12/2023Ownership: 0.354%Manchester Capital Management LLCBought 1,202,452 shares on 5/9/2023Ownership: 4.216%Simplex Trading LLCBought 1,100 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions ADIL Stock - Frequently Asked Questions Should I buy or sell Adial Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADIL shares. View ADIL analyst ratings or view top-rated stocks. What is Adial Pharmaceuticals' stock price forecast for 2023? 2 analysts have issued twelve-month target prices for Adial Pharmaceuticals' shares. Their ADIL share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 933.4% from the stock's current price. View analysts price targets for ADIL or view top-rated stocks among Wall Street analysts. How have ADIL shares performed in 2023? Adial Pharmaceuticals' stock was trading at $0.2150 on January 1st, 2023. Since then, ADIL shares have increased by 35.0% and is now trading at $0.2903. View the best growth stocks for 2023 here. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 324,800 shares, a decrease of 22.0% from the April 30th total of 416,400 shares. Based on an average daily volume of 671,600 shares, the days-to-cover ratio is currently 0.5 days. View Adial Pharmaceuticals' Short Interest. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 15th 2023. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? (ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. What is Adial Pharmaceuticals' stock symbol? Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL." Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Manchester Capital Management LLC (4.22%), Susquehanna International Group LLP (0.78%), Renaissance Technologies LLC (0.35%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III. View institutional ownership trends. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adial Pharmaceuticals' stock price today? One share of ADIL stock can currently be purchased for approximately $0.29. How much money does Adial Pharmaceuticals make? Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $8.28 million. The company earns $-12,730,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. How can I contact Adial Pharmaceuticals? Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com. This page (NASDAQ:ADIL) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.